Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.02 EUR
Change Today -0.017 / -44.74%
Volume 0.0
As of 3:35 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (YP1) Snapshot

Open
€0.02
Previous Close
€0.04
Day High
€0.03
Day Low
€0.02
52 Week High
05/20/15 - €0.19
52 Week Low
01/19/15 - €0.0020
Market Cap
41.5M
Average Volume 10 Days
2.3K
EPS TTM
--
Shares Outstanding
2.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (YP1)

Related News

No related news articles were found.

prima biomed ltd (YP1) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (YP1) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The company’s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. Prima BioMed Ltd. is based in Sydney, Australia.

prima biomed ltd (YP1) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$345.8K
Chief Scientific Officer and Chief Medical Of...
Total Annual Compensation: A$130.2K
Chief Technical Officer
Total Annual Compensation: A$356.2K
General Counsel and Company Secretary
Total Annual Compensation: A$231.7K
Compensation as of Fiscal Year 2015.

prima biomed ltd (YP1) Key Developments

Prima Biomed Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2015

Prima Biomed Ltd. reported consolidated earnings results for the year ended June 30, 2015. For the year, the company reported total other income was AUD 2,092,867 against AUD 3,140,066 a year ago. Loss before income tax expense was AUD 32,293,852 against AUD 13,329,774 a year ago. Loss for the year attributable to owners of the company was AUD 32,151,696 against AUD 13,343,381 a year ago. Basic and diluted loss per share was 2.02 cents against 0.93 cents a year ago. Net cash outflow from operating activities was AUD 7,786,982 against AUD 14,227,161 a year ago. Payments for plant and equipment were AUD 48,499 against AUD 103,675 a year ago.

Prima Biomed Ltd. Reports Cash Flow Results for the Fourth Quarter and Year Ended June 30, 2015

Prima Biomed Ltd. reported cash flow results for the fourth quarter and year ended June 30, 2015. For the quarter, net operating cash flows was AUD 2,565 million. For the year, net operating cash flows was AUD 6,892 million. Payment for acquisition of physical non-current assets was AUD 0.046 million.

Prima Biomed Ltd., Special/Extraordinary Shareholders Meeting, Jul 31, 2015

Prima Biomed Ltd., Special/Extraordinary Shareholders Meeting, Jul 31, 2015., at 11:00 AUS Eastern Standard Time. Location: K&L Gates,. Agenda: To consider the ratification of issue of warrants and shares to acquire Immutep S.A; to consider the ratification of issue of securities to Bergen Global Opportunity Fund, LP; to consider the ratification of issue of subscription shares to Ridgeback; to consider the approval of the issue of further securities to Ridgeback; and to consider the grant of director performance rights to Mr. Marc Voigt.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YP1:GR €0.02 EUR -0.017

YP1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for YP1.
View Industry Companies
 

Industry Analysis

YP1

Industry Average

Valuation YP1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 90.7x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 86.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.